Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 14:26:58 14/01/2026 GMT			5-day change	1st Jan Change
14,281.00 ^GBX	+1.95%		+0.41%	+3.57%

01:58pm	Sector Update: Health Care	MT
01:56pm	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Expected Supreme Court Decision on Tariffs	MT

Press Releases

12:30pm	Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale	AQ
12:29pm	Daiichi Sankyo - TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	AQ
01-13	AstraZeneca : Presentation (AZ JPM 2026 Presentation)	PU
01-08	Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit	BU
12-22	ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer	BU
12-19	Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies	AQ
12-18	AstraZeneca CEO: Europe risks losing production capacity for innovative medicines	AQ
12-16	Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards	AQ
12-15	ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	BU
12-15	AstraZeneca : Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	PU
12-12	Preserving The Status Quo: Boehringer Ingelheim Awarded Interim Injunction	AQ
12-04	Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides	AQ
12-04	AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH	BU
12-02	Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension	BU
12-01	Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board	AQ
11-26	IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers	BU
11-25	AstraZeneca : Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers	PU
11-24	Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology	AQ
11-24	AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment	AQ
11-21	AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth	BU
11-20	Koselugo (selumetinib) approved in the US	AQ
11-14	AstraZeneca : Director/PDMR Shareholding	PU
11-10	AstraZeneca : Director/PDMR Shareholding	PU
11-09	AstraZeneca : Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial	PU
11-09	Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

AstraZeneca CFO on M&A Strategy and Obesity Market

January 13, 2026 at 10:34 pm

AstraZeneca benefits from oncology momentum but valuation limits upside

November 19, 2025 at 12:43 pm

AstraZeneca's CEO reportedly considers listing in the United States

July 02, 2025 at 08:39 am